Bausch health companies inc BHC.US Overview Analysis

US StockHealth Care
(Powered by Quartr Logo)

BHC AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.

BHC Current Performance

-

Bausch health companies inc

1.31%

Avg of Sector

0.58%

S&P500

Top 10 High Relevance to BHC

  • ARTV Artiva biotherapeutics inc
    Value -Trend 1Swing Trading 4Whale Interest 2Dividend 1
    See more

BHC Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Price of BHC